We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Apollon Formularies plc | AQSE:APOL | Aquis Stock Exchange | Ordinary Share | IM00BJ0LRD77 | Ordinary shares |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.04 | -53.33% | 0.035 | 0.02 | 0.05 | 0.085 | 0.015 | 0.085 | 4,043,050 | 14:07:22 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMAPOL 30 June 2022 Apollon Formularies Plc ("Apollon" or the "Company") Total Voting Rights In accordance with the Financial Conduct Authority's Disclosure and Transparency Rules, the Company hereby announces that it has 752,725,356 ordinary shares of no par value each in issue, each share carrying the right to one vote. This figure of 752,725,356 ordinary shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules. The directors of the Company accept responsibility for the contents of this announcement. -ENDS- For further information please contact: Apollon Formularies Tel: +44 771 198 0221 Stene Jacobs stene@apollon.org.uk Peterhouse Capital Limited (Corporate Adviser) Tel: +44 207 220 9795 Guy Miller gm@peterhousecapital.com BlytheRay (Financial PR/IR-London) Tel: +44 207 138 3204 Tim Blythe/Megan Ray apollon@blytheray.com About Apollon and Apollon Jamaica Apollon Formularies plc is an international medical cannabis company headquartered in the United Kingdom. Apollon Formularies Jamaica Limited is a pharmaceutical company incorporated and operating in the Commonwealth of Jamaica. Apollon Jamaica is licensed by the Jamaican government's Cannabis Licensing Authority (CLA) to cultivate, perform research and development, process, and sell medical cannabis therapeutic products that include legal medical cannabis to treat various illnesses under medical supervision. Apollon and Apollon Jamaica are parties to a Commitment Agreement whereby Apollon is entitled to 95% of Apollon Jamaica's Net Profits, and per a Stock Pledge Agreement that includes Stephen D. Barnhill, M.D., Apollon is to be assigned the entire 49% equity interest of Apollon Jamaica held by Dr. Barnhill, which is the maximum interest in a medical cannabis company allowed to be held by a non-Jamaican, upon the CLA approving the assignment. END
(END) Dow Jones Newswires
June 30, 2022 07:33 ET (11:33 GMT)
1 Year Apollon Formularies Chart |
1 Month Apollon Formularies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions